Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2009 AND VI 27 AND IP 10
Results: 8
1
2
New Anticoagulants for the Prevention of Deep Venous Thrombosis: Time to Consider Cost Effectiveness?
- Published in:
- 2009
- By:
- Publication type:
- Opinion
3
Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 10, p. 797, doi. 10.2165/11313750-000000000-00000
- By:
- Publication type:
- Article
4
Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 10, p. 873, doi. 10.2165/11314750-000000000-00000
- By:
- Publication type:
- Article
5
Budget-Impact Analyses: A Critical Review of Published Studies.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 10, p. 807, doi. 10.2165/11313770-000000000-00000
- By:
- Publication type:
- Article
6
An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 10, p. 847, doi. 10.2165/10899510-000000000-00000
- By:
- Publication type:
- Article
7
A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 10, p. 829, doi. 10.2165/11313800-000000000-00000
- By:
- Publication type:
- Article
8
30 Years of Pharmaceutical Cost-Utility Analyses: Growth, Diversity and Methodological Improvement.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 10, p. 861, doi. 10.2165/11312720-000000000-00000
- By:
- Publication type:
- Article